Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy

Clinica Chimica Acta

Volumn 411, Issue 9-10, 2010, Pages 700-704

  Wu, Chia Chao ^a   Chen, Jin Shuen ^a   Lu, Kuo Cheng ^b   Chen, Chun Chi ^a   Lin, Shih Hua ^a   Chu, Pauling ^a   Sytwu, Huey Kang ^c   Lin, Yuh Feng ^a,d,e  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d Shuang Ho Hospital   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chemokine; Cytokine; Diabetic nephropathy; Inflammation

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY DYSFUNCTION; KIDNEY PARENCHYMA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA;

CHEMOKINE CCL2; CHEMOKINE CCL5; CHEMOKINES; CYTOKINES; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; KIDNEY; MALE; MIDDLE AGED; PROTEINURIA; RECEPTORS, INTERLEUKIN-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950459927     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.01.036     Document Type: Article

References (33)

1. Remuzzi G., Schieppati A., Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002, 346:1145-1151.
2. Caramori M.L., Mauer M. Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003, 12:273-282.
3. Ritz E., Rychlik I., Locatelli F., Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999, 34:795-808.
4. Wolf G., Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 2003, 14:1396-1405.
5. Galkina E., Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006, 17:368-377.
6. Fioretto P., Caramori M.L., Mauer M. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia 2008, 51:1347-1355.
7. Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
8. Cooper M.E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001, 44:1957-1972.
9. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 2004, 34:785-796.
10. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286-1292.
11. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
12. Fröhlich M., Imhof A., Berg G., Hutchinson W.L., Pepys M.B., Boeing H., et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000, 23:1835-1839.
13. Saraheimo M., Teppo A.M., Forsblom C., Fagerudd J., Groop P.H. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia 2003, 46:1402-1407.
14. Chow F.Y., Nikolic-Paterson D.J., Ma F.Y., Ozols E., Rollins B.J., Tesch G.H. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007, 50:471-480.
15. Lin J., Glynn R.J., Rifai N., Manson J.E., Ridker P.M., Nathan D.M., et al. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care 2008, 31:2338-2343.
16. Maeda S. Do inflammatory cytokine genes confer susceptibility to diabetic nephropathy?. Kidney Int 2008, 74:413-415.
17. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008, 19:433-442.
18. Evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease.
19. Ha H., Yu M.R., Choi Y.J., Kitamura M., Lee H.B. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 2002, 13:894-902.
20. Goh S.Y., Cooper M.E. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008, 93:1143-1152.
21. Bohlender J.M., Franke S., Stein G., Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005, 289:F645-F659.
22. Lee F.T., Cao Z., Long D.M., Panagiotopoulos S., Jerums G., Cooper M.E., et al. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 2004, 15:2139-2151.
23. Mezzano S., Droguett A., Burgos M.E., Ardiles L.G., Flores C.A., Aros C.A., et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int 2003, S64-S70. Suppl.
24. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008, 294:F697-F701.
25. Chiarelli F., Cipollone F., Mohn A., Marini M., Iezzi A., Fazia M., et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 2002, 25:1829-1834.
26. Mezzano S.A., Barría M., Droguett M.A., Burgos M.E., Ardiles L.G., Flores C., et al. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int 2001, 60:1366-1377.
27. Jefferson J.A., Shankland S.J., Pichler R.H. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 2008, 74:22-36.
28. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
29. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898.
30. Bending D., De La Peña H., Veldhoen M., Phillips J.M., Uyttenhove C., Stockinger B., et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009.
31. Bradshaw E.M., Raddassi K., Elyaman W., Orban T., Gottlieb P.A., Kent S.C., et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol 2009, 183:4432-4439.
32. Utimura R., Fujihara C.K., Mattar A.L., Malheiros D.M., Noronha I.L., Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003, 63:209-216.
33. McCormick B.B., Sydor A., Akbari A., Fergusson D., Doucette S., Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 2008, 52:454-463.